Sudeep Pharma

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0QPI01025
  • NSEID: SUDEEPPHRM
  • BSEID: 544619
INR
1,041.50
-70.4 (-6.33%)
BSENSE

Oct 09

BSE+NSE Vol: 3.64 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.64 lacs (214.43%) Volume

Shareholding (Jun 2026)

FII

1.81%

Held by 17 FIIs

DII

15.65%

Held by 18 DIIs

Promoter

76.15%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0% over the last 5 years

 
2

Positive results in Mar 26

3

With ROE of 19.6, it has a Very Expensive valuation with a 8.9 Price to Book Value

 
4

Majority shareholders : Promoters

 
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 11,764 Cr ()

stock-summary
P/E

69.00

stock-summary
Industry P/E

36

stock-summary
Dividend Yield

0.13%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

14.31

Revenue and Profits:
Net Sales:
158 Cr
(Quarterly Results - Jun 2026)
Net Profit:
41 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.13%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.72%
0%
29.72%
6 Months
69.69%
0%
69.69%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Sudeep Pharma for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Change in Management

05-Oct-2026 | Source : BSE

We wish to inform the changes in the SMP of the Company arising due to completion of contractual arrangements between the company and Mr. Sendhil Pani Managing Director of Sudeep Pharma USA Inc. (Wholly Owned Subsidiary of Sudeep Pharma Limited) w.e.f. 2nd October 2026.

Closure of Trading Window

25-Sep-2026 | Source : BSE

Intimation for Closure of Trading window w.e.f. 1st October 2026

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

23-Sep-2026 | Source : BSE

This is to inform that the officials of the Company will be attending the Investor Conference organized by Nuvama Emerging India CEO Forum 2026 on 28th September 2026 at 10:00 a.m. in Mumbai.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
33.98
Debt to EBITDA (avg)
0.72
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.65
Tax Ratio
23.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.46%
ROCE (avg)
24.88%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
69
Industry P/E
36
Price to Book Value
14.31
EV to EBIT
61.20
EV to EBITDA
57.11
EV to Capital Employed
13.79
EV to Sales
19.73
PEG Ratio
NA
Dividend Yield
0.13%
ROCE (Latest)
22.53%
ROE (Latest)
19.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (5.47%)

FIIs

Held by 17 FIIs (1.81%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (2.95%)

Individual Investors Holdings

4.89%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.68",
          "val2": "80.17",
          "chgp": "31.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.19",
          "val2": "28.89",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.76",
          "val2": "1.97",
          "chgp": "-10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "33.83",
          "val2": "25.77",
          "chgp": "31.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.08%",
          "val2": "36.04%",
          "chgp": "1.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Sudeep Pharma"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Sudeep Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQstock-summary
Jun'26
Mar'26
Change(%)
Net Sales
105.68
80.17
31.82%
Operating Profit (PBDIT) excl Other Income
39.19
28.89
35.65%
Interest
1.76
1.97
-10.66%
Exceptional Items
0.00
0.00
Standalone Net Profit
33.83
25.77
31.28%
Operating Profit Margin (Excl OI)
37.08%
36.04%
1.04%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026

Annual Results Snapshot (Consolidated) - Mar'26stock-summary
Mar'26
Mar'25
Change(%)
Net Sales
642.26
502.00
27.94%
Operating Profit (PBDIT) excl Other Income
221.91
189.95
16.83%
Interest
7.60
5.85
29.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
172.89
138.73
24.62%
Operating Profit Margin (Excl OI)
34.55%
37.84%
-3.29%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details